Genetic Technologies Limited's ROA from the fourth quarter of 2024 to the fourth quarter of 2019 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Genetic Technologies Limited's ROA in the fourth quarter of 2024?
Genetic Technologies Limited recorded a cumulative net loss of $-12 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on assets (ROA) of -251.56%.

However, within the Healthcare sector 962 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2024 from to 4894.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2019) IV. Quarter
Y / Y Total Assets Change	-58.27 %	-61.32 %	-69.53 %	-63.14 %	-48.57 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-6	-6	-6	-6
Return On Assets (TTM)	-251.56 %	-103.32 %	-81.79 %	-61.11 %	-48.81 %
GENE's Total Ranking	# 4894	#	#	#	# 4894
Total Assets (TTM) in million	4	4	5	6	10
Seq. Total Assets Change	0 %	-11.37 %	-24.67 %	-37.5 %	-7.32 %
Seq. Net Income Change	-	-	-	-	-

GENE's 5 Years Annual ROA >> Back to GENE Management Effectiveness >> Compare GENE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 152
Sector	# 963
Overall	# 4806

Return On Assets Statistics
High	Average	Low
-30.71 %	-96.15 %	-196.8 %
(Jun 30 2021)		(Jun 30 2019)

Financial Statements
Genetic Technologies Limited's Assets	$ 4 million	GENE's Balance sheet
Genetic Technologies Limited's Income	$ -12 million	Quarterly GENE's Income Statement
GENE's Income by Division		See GENE's Income by Division

Annual Return On Assets	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021	(Jun 30 2020) FY 2020
Y / Y Total Assets Change	-37.5 %	-38.79 %	-16.88 %	51.35 %	293.71 %
Total Assets in million	6	10	16	19	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-12	-8	-5	-5	-4
Annual Return On Assets	-194.25 %	-79.91 %	-32 %	-27.18 %	-32.86 %

GENE's 5 Years Annual ROA >> Back to GENE Management Effectiveness >> Compare GENE ROA to its Competitors

More Return On Assets Ratios
GENE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GENE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GENE's Competitors
Subscribers only: Roa for Genetic Technologies Limited's Suppliers
Subscribers only: Return On Assets for GENE's Customers

You may also want to know
GENE's Roi	GENE's Inventory Turnover Ratio	GENE's Growth Rates	GENE's Dividend Comparisons
	GENE's Profitability Ratios	GENE's Asset Turnover Ratio	GENE's Dividend Growth
GENE's Roe	GENE's Valuation Ratios	GENE's Financial Strength Ratios	GENE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.